Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer

作者：Haoran Yang, Qingmei Deng, Tun Ni, Yu Liu, Li Lu, Haiming Dai, Hongzhi Wang, Wulin Yang · 发表于：International Journal of Biological Sciences · 年份：2021 · DOI：10.7150/ijbs.64714 · 被引用次数：92 · 研究领域：Cancer, Lipids, and Metabolism、Liver Disease Diagnosis and Treatment、Peroxisome Proliferator-Activated Receptors

These results suggest that activation of the LPL/FABP4/CPT1 axis is essential for LCSCs maintenance, which acts synergistically with a variety of up-regulated oncogenic signals that drive the hepatocyte-LCSCs transdifferentiation during NASH to HCC progression. Thus, targeting the LPL/FABP4/CPT1 axis may provide a potential direction for NASH-related HCC prevention.